Not yet recruitingPhase 2

Myocardial Metabolic Flux in Pulmonary Arterial Hypertension

Myocardial Metabolic Flux in Patients With Pulmonary Arterial Hypertension (PAH) in Response to GLP-1 Agonist Therapy: a Physiological Study Using 31-Phosphorus MR Spectroscopy

Lead sponsor

Imperial College London

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

Study population

Hypertension

Eligibility highlights

•BMI ≥30

Primary endpoint

•The phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07737522

Org study ID370988

Timeline

Milestones

Study first posted2026-07-30actual

Last update posted2026-07-30actual

Study start2026-10-01estimated

Primary completion2028-10-01estimated

Study completion2029-04-01estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Hypertension

Who can enroll

Minimum age18 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

- 1. Diagnosis of Group 1 PAH confirmed by right heart catheterisation under the National Pulmonary Hypertension Service, Royal Brompton Hospital, part of GSTT Foundation Trust 2. Age over 18, less than 85 years 3. Able to give informed consent 4. On a stable dose of PAH-specific therapies (e.g., ERA, PDE5i) for at least 3 months.

5. Clinically justified prescription of GLP-1 agonist Semaglutide based on following criteria: BMI > 30 or BMI > 27 with at least one cardiovascular co-morbidity (systemic hypertension, diabetes, pre-diabetes, COPD, atrial fibrillation, dyslipidaemia, sleep disordered breathing)

Exclusion criteria

•• 1. Pregnancy

-2. Myocardial infarction within the previous 3 months

-3. Contraindications to MRI: Pacemakers, metallic implants, or severe claustrophobia.

-4. Severe renal impairment: eGFR < 15ml/min/1.73m.

-5. Current use of SGLT2 inhibitors or GLP-1 agonist therapy (which significantly alter fuel substrate preference) or insulin therapy that cannot be held for the fasting scan

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist

Time frame:12 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.